There is an estimated rate of between 7 and 3,000 ME/CFS sufferers in a population of 100,000. Between 836,000 and 2.5 million people in the US suffer from ME/CFS. Although there is not a known cause of ME/CFS, sufferers seem to have an inflammation of the dura and meninges that surround the spinal cord and brain. Immunological and endocrine abnormalities have been observed in some people with ME/CFS. Cannabinoids may help treat some of the symptoms of ME/CFS, e.g. chronic muscular & joint pain, chronic fatigue syndrome (CFS), heart palpitations and headaches.
Explore A-Z conditions
Cannabis for Myalgic Encephalomyelitis (ME)
Research Overview
Animal Study
16
Clinical Trial
3
Laboratory Study
2
Meta-analysis
7
Total studies
Myalgic Encephalomyelitis (ME)
28
Positive
24 studies
86%
Inconclusive
3 studies
11%
Negative
1 studies
4%
Do I qualify?
Select your state from the drop down and we’ll let you know.
Relevant studies
The information in our comprehensive A to Z encyclopedia comes from real scientific studies.
Uncover the detailed results of these studies and find out how effective medical marijuana is for dozens of conditions.
- A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis.
- A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis
- Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis
- Big conductance calcium-activated potassium channel openers control spasticity without sedation
- Biphasic effects of THC in memory and cognition.